title: Effects of combination therapy consisting of moderate-dose intravenous immunoglobulin G, pulsed methylprednisolone and pravastatin in children with steroid-resistant nephrosis.
authors.forename: K
authors.initials: K
authors.lastname: Kano
authors.forename: E
authors.initials: E
authors.lastname: Hoshi
authors.forename: S
authors.initials: S
authors.lastname: Ito
authors.forename: K
authors.initials: K
authors.lastname: Kyo
authors.forename: Y
authors.initials: Y
authors.lastname: Yamada
authors.forename: T
authors.initials: T
authors.lastname: Ando
authors.forename: O
authors.initials: O
authors.lastname: Arisaka
authors.forename: S
authors.initials: S
authors.lastname: Tomita
authors.forename: Y
authors.initials: Y
authors.lastname: Ueda
mesh_terms: D000924:Anticholesteremic Agents / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D007223:Infant; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage*; D009404:Nephrotic Syndrome / Q000188:drug therapy* / Q000628:therapy*; D017035:Pravastatin / Q000008:administration & dosage*
chemical_list: D000924:Anticholesteremic Agents; D005938:Glucocorticoids; D016756:Immunoglobulins, Intravenous; D017035:Pravastatin; D008775:Methylprednisolone